| 2.72 0.13 (5.02%) | 08-27 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 3.46  |
1-year : | 4.05 |
| Resists | First : | 2.97 |
Second : | 3.46 |
| Pivot price | 2.09 |
|||
| Supports | First : | 1.97 |
Second : | 1.36 |
| MAs | MA(5) : | 2.38 |
MA(20) : | 1.98 |
| MA(100) : | 1.74 |
MA(250) : | 2.06  |
|
| MACD | MACD : | 0.2 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 87.2 |
D(3) : | 88.7 |
| RSI | RSI(14): 84 |
|||
| 52-week | High : | 3.57 | Low : | 1.35 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ CMMB ] has closed above the upper band by 12.0%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 59.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 2.97 - 2.98 | 2.98 - 2.99 |
| Low: | 2.55 - 2.56 | 2.56 - 2.57 |
| Close: | 2.7 - 2.72 | 2.72 - 2.73 |
Chemomab Therapeutics Ltd. operates as a clinical-stage biotechnology firm, dedicated to identifying and advancing novel treatments for inflammatory and fibrotic conditions. Its leading experimental drug candidate, CM-101, is a humanized monoclonal antibody specifically engineered to impede the core function of soluble chemokine CCL24. This potential therapy is currently under investigation for its efficacy in managing primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Established in 2011, the company, formerly known as Anchiano Therapeutics Ltd., adopted its current name, Chemomab Therapeutics Ltd., in March 2021 and is headquartered in Tel Aviv, Israel.
Wed, 19 Aug 2026
Chemomab Expects a 2027 Rheumatoid Arthritis Trial in a $24B Market - Stock Titan
Wed, 19 Aug 2026
Chemomab Therapeutics (CMMB) 10K Form and Latest SEC Filings 2026 - MarketBeat
Fri, 14 Aug 2026
Chemomab Therapeutics (CMMB) Edges Lower to $1.89 as Stock Tests Support Zone - Liquidity Sweep - vinanet.vn
Thu, 13 Aug 2026
Chemomab Therapeutics (CMMB) gains 5.2% stake holder in Touchstone Global - Stock Titan
Mon, 10 Aug 2026
Chemomab Therapeutics (CMMB) holder Erik Otto reports 1.2% ADS ownership - Stock Titan
Sat, 08 Aug 2026
Chemomab Therapeutics (CMMB) Jumps 7.2% as Shares Push Toward Key Resistance - Golden Cross - vinanet.vn
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 7 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 7 (%) |
| Held by Institutions | 8.2 (%) |
| Shares Short | 156 (K) |
| Shares Short P.Month | 143 (K) |
| EPS | -0.96 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.2 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -46.3 % |
| Return on Equity (ttm) | -82.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.07 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -2.84 |
| PEG Ratio | 0 |
| Price to Book value | 2.26 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|